Terminated PHASE2 INTERVENTIONAL NCT00040391

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer

Sponsor: Celgene Corporation

Conditions Colorectal Neoplasms Diarrhea

Interventions 5-fluorouracil Investigational drug Irinotecan Leucovorin

Updated 6 times since 2017 Last updated: Nov 30, 2016 Started: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other Colorectal Neoplasms trials with similar outcome

Browse all Colorectal Neoplasms trials

Listed as NCT00040391, this PHASE2 trial focuses on Colorectal Neoplasms and Diarrhea and remains terminated or withdrawn. Sponsored by Celgene Corporation, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Pfizer

Data source: Celgene Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Burlington, United States , Charleston, United States , Concord, United States , Dallas, United States , East Lansing, United States , East Setauket, United States , Germantown, United States , Gilroy, United States , Greenville, United States and 16 more locations